Autoantibodies to oxidized low-density lipoprotein in patients with Type 2 diabetes mellitus

Rebecca M. Hsu, Sridevi Devaraj, Ishwarlal Jialal

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Background: Oxidation of low-density lipoprotein (LDL) is a crucial step in atherogenesis. There is an urgent need for direct measures of in vivo oxidative stress. Autoantibodies against oxidized low-density lipoprotein (Ab against Ox-LDL) are a direct measure of oxidative stress and predict cardiovascular disease. Our aim was to evaluate an ELISA for Ab against Ox-LDL in Type 2 diabetes, a condition with increased oxidative stress. Methods: Ab against Ox-LDL were measured by ELISA and expressed as a ratio of Ox-LDL to native LDL (N-LDL). Samples were obtained from 45 Type 2 diabetic patients and 25 matched controls before and after supplementation with alpha tocopherol (AT, 1200 IU/day). Results: The assay had good precision. While there was no interference with bilirubin and hemolysis, triglycerides 500 mg/dl increased antibody titer, which was abrogated by airfuging. Compared to controls, significantly increased titers of Ab against Ox-LDL were found in diabetics (diabetes mellitus Type 2) with macrovascular disease (DM2-MV), but not without macrovascular disease (DM2) (DM2: 1.32 ± 0.33; DM2-MV: 1.48 ± 0.44 vs. controls, 1.21 ± 0.28; p < 0.05). AT supplementation significantly decreased titers of Ab against Ox-LDL in both diabetic groups (p < 0.01). Conclusion: This assay may serve as a future test for the assessment of cardiovascular risk especially in patients with increased oxidative stress.

Original languageEnglish (US)
Pages (from-to)145-150
Number of pages6
JournalClinica Chimica Acta
Volume317
Issue number1-2
DOIs
StatePublished - 2002
Externally publishedYes

Fingerprint

Medical problems
LDL Lipoproteins
Autoantibodies
Type 2 Diabetes Mellitus
Oxidative stress
Oxidative Stress
Assays
Enzyme-Linked Immunosorbent Assay
oxidized low density lipoprotein
alpha-Tocopherol
Hemolysis
Bilirubin
Atherosclerosis
Triglycerides
Cardiovascular Diseases
Oxidation
Antibodies

Keywords

  • Autoantibodies against oxidized low-density lipoprotein
  • Immunoassay
  • Type 2 diabetes mellitus

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry

Cite this

Autoantibodies to oxidized low-density lipoprotein in patients with Type 2 diabetes mellitus. / Hsu, Rebecca M.; Devaraj, Sridevi; Jialal, Ishwarlal.

In: Clinica Chimica Acta, Vol. 317, No. 1-2, 2002, p. 145-150.

Research output: Contribution to journalArticle

Hsu, Rebecca M. ; Devaraj, Sridevi ; Jialal, Ishwarlal. / Autoantibodies to oxidized low-density lipoprotein in patients with Type 2 diabetes mellitus. In: Clinica Chimica Acta. 2002 ; Vol. 317, No. 1-2. pp. 145-150.
@article{20c8545941db47bf87792ba21fc0114a,
title = "Autoantibodies to oxidized low-density lipoprotein in patients with Type 2 diabetes mellitus",
abstract = "Background: Oxidation of low-density lipoprotein (LDL) is a crucial step in atherogenesis. There is an urgent need for direct measures of in vivo oxidative stress. Autoantibodies against oxidized low-density lipoprotein (Ab against Ox-LDL) are a direct measure of oxidative stress and predict cardiovascular disease. Our aim was to evaluate an ELISA for Ab against Ox-LDL in Type 2 diabetes, a condition with increased oxidative stress. Methods: Ab against Ox-LDL were measured by ELISA and expressed as a ratio of Ox-LDL to native LDL (N-LDL). Samples were obtained from 45 Type 2 diabetic patients and 25 matched controls before and after supplementation with alpha tocopherol (AT, 1200 IU/day). Results: The assay had good precision. While there was no interference with bilirubin and hemolysis, triglycerides 500 mg/dl increased antibody titer, which was abrogated by airfuging. Compared to controls, significantly increased titers of Ab against Ox-LDL were found in diabetics (diabetes mellitus Type 2) with macrovascular disease (DM2-MV), but not without macrovascular disease (DM2) (DM2: 1.32 ± 0.33; DM2-MV: 1.48 ± 0.44 vs. controls, 1.21 ± 0.28; p < 0.05). AT supplementation significantly decreased titers of Ab against Ox-LDL in both diabetic groups (p < 0.01). Conclusion: This assay may serve as a future test for the assessment of cardiovascular risk especially in patients with increased oxidative stress.",
keywords = "Autoantibodies against oxidized low-density lipoprotein, Immunoassay, Type 2 diabetes mellitus",
author = "Hsu, {Rebecca M.} and Sridevi Devaraj and Ishwarlal Jialal",
year = "2002",
doi = "10.1016/S0009-8981(01)00767-7",
language = "English (US)",
volume = "317",
pages = "145--150",
journal = "Clinica Chimica Acta",
issn = "0009-8981",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - Autoantibodies to oxidized low-density lipoprotein in patients with Type 2 diabetes mellitus

AU - Hsu, Rebecca M.

AU - Devaraj, Sridevi

AU - Jialal, Ishwarlal

PY - 2002

Y1 - 2002

N2 - Background: Oxidation of low-density lipoprotein (LDL) is a crucial step in atherogenesis. There is an urgent need for direct measures of in vivo oxidative stress. Autoantibodies against oxidized low-density lipoprotein (Ab against Ox-LDL) are a direct measure of oxidative stress and predict cardiovascular disease. Our aim was to evaluate an ELISA for Ab against Ox-LDL in Type 2 diabetes, a condition with increased oxidative stress. Methods: Ab against Ox-LDL were measured by ELISA and expressed as a ratio of Ox-LDL to native LDL (N-LDL). Samples were obtained from 45 Type 2 diabetic patients and 25 matched controls before and after supplementation with alpha tocopherol (AT, 1200 IU/day). Results: The assay had good precision. While there was no interference with bilirubin and hemolysis, triglycerides 500 mg/dl increased antibody titer, which was abrogated by airfuging. Compared to controls, significantly increased titers of Ab against Ox-LDL were found in diabetics (diabetes mellitus Type 2) with macrovascular disease (DM2-MV), but not without macrovascular disease (DM2) (DM2: 1.32 ± 0.33; DM2-MV: 1.48 ± 0.44 vs. controls, 1.21 ± 0.28; p < 0.05). AT supplementation significantly decreased titers of Ab against Ox-LDL in both diabetic groups (p < 0.01). Conclusion: This assay may serve as a future test for the assessment of cardiovascular risk especially in patients with increased oxidative stress.

AB - Background: Oxidation of low-density lipoprotein (LDL) is a crucial step in atherogenesis. There is an urgent need for direct measures of in vivo oxidative stress. Autoantibodies against oxidized low-density lipoprotein (Ab against Ox-LDL) are a direct measure of oxidative stress and predict cardiovascular disease. Our aim was to evaluate an ELISA for Ab against Ox-LDL in Type 2 diabetes, a condition with increased oxidative stress. Methods: Ab against Ox-LDL were measured by ELISA and expressed as a ratio of Ox-LDL to native LDL (N-LDL). Samples were obtained from 45 Type 2 diabetic patients and 25 matched controls before and after supplementation with alpha tocopherol (AT, 1200 IU/day). Results: The assay had good precision. While there was no interference with bilirubin and hemolysis, triglycerides 500 mg/dl increased antibody titer, which was abrogated by airfuging. Compared to controls, significantly increased titers of Ab against Ox-LDL were found in diabetics (diabetes mellitus Type 2) with macrovascular disease (DM2-MV), but not without macrovascular disease (DM2) (DM2: 1.32 ± 0.33; DM2-MV: 1.48 ± 0.44 vs. controls, 1.21 ± 0.28; p < 0.05). AT supplementation significantly decreased titers of Ab against Ox-LDL in both diabetic groups (p < 0.01). Conclusion: This assay may serve as a future test for the assessment of cardiovascular risk especially in patients with increased oxidative stress.

KW - Autoantibodies against oxidized low-density lipoprotein

KW - Immunoassay

KW - Type 2 diabetes mellitus

UR - http://www.scopus.com/inward/record.url?scp=0036157629&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036157629&partnerID=8YFLogxK

U2 - 10.1016/S0009-8981(01)00767-7

DO - 10.1016/S0009-8981(01)00767-7

M3 - Article

C2 - 11814469

AN - SCOPUS:0036157629

VL - 317

SP - 145

EP - 150

JO - Clinica Chimica Acta

JF - Clinica Chimica Acta

SN - 0009-8981

IS - 1-2

ER -